Position in ATAI
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$606,713
New position
Shares Held
171,388
first reported quarter
Ownership
0.047%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Derivatives in ATAI
reported options exposure · as of Mar 31, 2026CallValue
$924,648
CallShares
261,200
PutValue
$375,594
PutShares
106,100
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026CITADEL ADVISORS LLC holds $5,783,571,443 across 373 Biotechnology names. ATAI ranks #251 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
2,182,571 | $356,894,009 | |
| 2 | ONC |
BeOne Medicines Ltd.
|
1,032,298 | $306,561,536 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
4,512,634 | $254,918,694 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
1,259,444 | $238,097,887 | |
| 5 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
453,843 | $237,573,195 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
3,173,940 | $235,696,783 | |
| 7 | TERN |
Terns Pharmaceuticals, Inc.
|
3,218,810 | $169,695,662 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
1,551,900 | $163,570,260 |
All Filings in ATAI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $375,594 | 106,100 | Put | Defined | 2026-05-15 | |
| 2026-03-31 | $924,648 | 261,200 | Call | Defined | 2026-05-15 | |
| 2026-03-31 | $606,713 | 171,388 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||